The strong Q1 beat and reaffirmed guidance with accelerating 3870 pump shipments in Q2-Q3 2026 suggest upside potential. Monitor Q2 2026 results for 3870 revenue ramp and margin expansion — a beat on Q2 guidance would confirm the product cycle thesis.
Price Chart
Executive Summary
iRadimed reported Q1 2026 revenue of $22.0M (+13% YoY) and GAAP diluted EPS of $0.45 (+22% YoY), beating consensus estimates of $0.45 EPS on $21.3M revenue. The company reaffirmed full-year 2026 guidance and highlighted strong early orders for its next-generation 3870 MRI-compatible IV infusion pump, with significant shipments expected in Q2.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $22.0M vs consensus $21.3M (beat)
- GAAP diluted EPS $0.45 vs consensus $0.45 (in line)
- Revenue grew 13% YoY to $22.0M from $19.5M
- GAAP diluted EPS grew 22% YoY to $0.45 from $0.37
- Operating income $7.2M, up 33% YoY
- Operating cash flow $8.3M, up 93% YoY
- Gross margin improved to 77% from 76% YoY
- Full-year 2026 guidance reaffirmed: revenue $91M-$96M, GAAP EPS $1.90-$2.05
- Q2 2026 guidance: revenue $20M-$21M, GAAP EPS $0.40-$0.44
- Declared $0.20/share quarterly dividend
- Commercial launch of next-gen 3870 pump with strong early orders
Financial Impact
Revenue beat of ~$0.7M (3.3%) vs consensus; EPS in line; operating cash flow nearly doubled YoY to $8.3M
Risk Factors
- Q2 2026 guidance midpoint ($20.5M revenue) implies sequential decline from Q1's $22.0M
- Full-year guidance implies H2-weighted revenue, creating execution risk on 3870 ramp
- Stock trades at ~12x forward EPS (based on $1.90-$2.05 guidance) — limited multiple expansion without sustained beat
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285905 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 12w ago | 8-K | $90.86 $84.63 | ▼ −6.86% | ▼ −9.31% | $83.95 (−7.61%) |
Jul 31, 2026 12w ago | Press Release | $90.86 $84.63 | ▼ −6.86% | ▼ −9.31% | $83.95 (−7.61%) |
Jul 24, 2026 13w ago | Press Release | $95.08 $87.65 | ▼ −7.81% | ▼ −11.52% | $83.95 (−11.71%) |
Jun 4, 2026 20w ago | Insider Cluster | $93.07 $86.38 | ▼ −7.19% | ▼ −11.19% | $83.95 (−9.80%) |
May 20, 2026 22w ago | Press Release | $90.40 $86.95 | ▼ −3.82% | ▼ −8.82% | $83.95 (−7.13%) |
May 1, 2026 25w ago | Press Release | $87.15 $94.83 | ▲ +8.81% | ▲ +5.74% | $83.95 (−3.67%) |
Apr 27, 2026 26w ago | Press Release | $89.08 $94.08 | ▲ +5.61% | ▲ +0.84% | $83.95 (−5.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers